Literature DB >> 17532199

Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency.

Elisabeth Bernspång1, Tomas Sveger, Eeva Piitulainen.   

Abstract

INTRODUCTION: Individuals with severe alpha-1-antitrypsin (AAT) deficiency have a well-known risk of developing emphysema but it is not known at which age the first symptoms occur and lung function declines. The aim of this study was to examine the prevalence of smoking, respiratory symptoms and lung function at the age of 30 in AAT-deficient individuals (PiZ and PiSZ) identified by neonatal screening.
MATERIAL AND METHODS: One hundred and seven PiZ, 45 PiSZ and 197 control subjects (PiMM) filled in a questionnaire regarding smoking habits and symptoms. Ninety PiZ, 40 PiSZ and 84 control subjects underwent spirometry including FEV(1) and FVC.
RESULTS: Twenty-one percent of PiZ, 23% of PiSZ and 34% of PiMM subjects had smoked at some time (p<0.05). Sixty-five percent of PiZ, 55% of PiSZ and 35% of PiMM ever-smokers reported shortness of breath on exertion (p<0.05 PiZ vs PiMM). The mean FEV(1) was 101% predicted (95% CI 98-104) in PiZ, 101% predicted (95% CI 97-106) in PiSZ, and 96% predicted (95% 93-98) in PiMM individuals (p<0.05). There was no difference in mean FEV(1) when comparing ever- and neversmokers in the different Pi groups separately.
CONCLUSION: At the age of 30, the AAT-deficient individuals in this cohort report more symptoms than the control subjects. Smoking is less common in the cohort compared to controls. Their lung function is normal.

Entities:  

Mesh:

Year:  2007        PMID: 17532199     DOI: 10.1016/j.rmed.2007.04.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Clinical utility gene card for: α-1-antitrypsin deficiency.

Authors:  Sabina Janciauskiene; Ilaria Ferrarotti; Florian Laenger; Danny Jonigk; Maurizio Luisetti
Journal:  Eur J Hum Genet       Date:  2011-01-19       Impact factor: 4.246

Review 2.  Why is Disease Penetration So Variable? Role of Genetic Modifiers of Lung Function in Alpha-1 Antitrypsin Deficiency.

Authors:  Brian D Hobbs; Michael H Cho
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

Review 3.  Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease: a look at future precision medicine approaches.

Authors:  Auyon J Ghosh; Brian D Hobbs
Journal:  Expert Rev Respir Med       Date:  2022-01-13       Impact factor: 3.772

Review 4.  Genes and chronic obstructive pulmonary disease.

Authors:  Marilyn G Foreman; Michael Campos; Juan C Celedón
Journal:  Med Clin North Am       Date:  2012-03-06       Impact factor: 5.456

5.  Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.

Authors:  Eeva Piitulainen; Behrouz Mostafavi; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-02-02

Review 6.  Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.

Authors:  Kenneth R Chapman; Joanna Chorostowska-Wynimko; A Rembert Koczulla; Ilaria Ferrarotti; Noel G McElvaney
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-01-31

7.  Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.

Authors:  Behrouz Mostafavi; Eeva Piitulainen; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-02-28

8.  Endotoxin receptor CD14 in PiZ alpha-1-antitrypsin deficiency individuals.

Authors:  Caroline S Sandström; Natalia Novoradovskaya; Corrado M Cilio; Eeva Piitulainen; Tomas Sveger; Sabina Janciauskiene
Journal:  Respir Res       Date:  2008-04-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.